Inhibitionn of the tissue factor pathway of coagulation by recombinantt nematode anticoagulant protein c2 in patientss undergoing elective coronary stent implantation: effectss on hemostatic and inflammatory parameters

GGeneration of platelet-derived microparticles in patients undergoing cardiac surgery is not affected by complement activation

Combined Use of a Factor XIIa Inhibitor with a Polycarboxybetaine Coating Creates Potent Anticoagulation with Preserved Hemostasis during Ambulatory, 24-hour, Rabbit Extracorporeal Life Support.

The combined use of FXII900 and PCB coating provides potent anticoagulation while preserving hemostatic function for at least 15 hours, demonstrating a promising path toward safer anticoagulation during ECLS.

CARDIO-VASCULAR DISEASE COMBAT: BACTERIAL SCREENING FOR POTENT BLOOD CLOT- DIGESTIBLE (FIBRINOLYTIC) PROTEASES

Proteases (Fibrinolytic) enzymes have implicit function in cascade system, accelerating the switch of prothrombin to thrombin following degradation of fibrin or blood clots, unfolding the issues of thrombotic disorders related to cardiovascular diseases. Common blood flow obstructions due to embolism and thrombosis lea...

Targeting α6β1 Integrin Signaling with Pranlukast to Modulate Venous Endothelium Function and Reduce Post-Thrombotic Vein Wall Injury.

BACKGROUND Post-thrombotic syndrome (PTS) develops in 20-50% of patients following deep vein thrombosis (DVT) due to persistent vein wall injury, inflammation, and fibrotic remodeling. Current anticoagulant therapies do not directly address PTS pathogenesis and carry bleeding risks. We characterized the extracellular m...

Update on the cardiovascular application of targeting factor XI

Cardiovascular diseases remain the leading global cause of morbidity and mortality, and thrombotic events contribute substantially to their clinical burden. Established anticoagulants, including vitamin K antagonists and direct oral anticoagulants, reduce thromboembolic events but remain limited by bleeding risk in sel...

Perioperative Management of Patients on Factor XI or Factor XIa Inhibitors.

Periprocedural data from completed Phase 2 clinical trials demonstrate that for primary venous thromboprophylaxis of patients undergoing major orthopedic surgery who are at risk of major bleeding, strategies to inhibit FXI result in a lower risk of venous thromboembolism and lower clinically relevant bleeding compared...